 Home > Medical News > Latest Medical News > Challenge AstraZeneca's first new category of complement drug Aspaveli in more than ten years to obtain approval!

Challenge AstraZeneca's first new category of complement drug Aspaveli in more than ten years to obtain approval!

 Last Update: 2021-12-27
 Source: Internet
 Author: User

Tags

standard states elements

immune system structure

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Compilenewborn

On December 15th, Apellis Pharmaceuticals and Swedish Orphan Biovitrum (SOBI) jointly announced that the European Commission has approved Aspaveli (pegcetacoplan) for the treatment of episodes of anemia after receiving complement C5 inhibitors for at least 3 months.

Pegcetacoplan is the first and only therapy targeting complement C3 to receive regulatory approval

Pegcetacoplan represents the first new category of complement drugs approved by the regulatory authorities in more than a decade, and has the potential to improve the standard of care for PNH patients

PNH is a rare, chronic, and life-threatening blood disease.

This approval is based on the results of the head-to-head phase 3 study of PEGASUS

Pegcetacoplan is a targeted complement C3 inhibitor, C3 is the upstream signaling molecule of C5

Soliris and Ultomiris are two complement C5 inhibitors sold by Alexion.

In December 2020, AstraZeneca announced that it would acquire Alexion for $39 billion in cash and stock

Reference source: Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.